Optic IconOptic Logo
|
SearchCollectionsBenchmarks

TILT-123

1 product

3 abstracts

1 target

Target
tumor necrosis factor
Abstract
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
Org: TILT Biotherapeutics, Mayo Clinic, Docrates Cancer Center, Cancer Gene Therapy Group, Merck & Co., Inc.,
Abstract
Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cell Therapy Manufacturing Center, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Cell Therapy Manufacturing Center, a joint venture between MD Anderson Cancer Center and Resilience,
Abstract
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
Org: Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China, Center for Clinical Development and Research, Pharmaceutical Technology Inc, Shanghai Cell Therapy Group, Shanghai, China, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, China,
Product
TILT-123 + pembrolizumab